<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lin J</submitter><funding>Natural Science Foundation of Education Department of Anhui Province</funding><funding>Natural Science Foundation of Anhui Province</funding><funding>National Natural Science Foundation of China</funding><funding>Anhui Provincial Special Fund for Clinical Medical Research Transformation</funding><pagination>2202</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12708435</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Hepatocellular carcinoma (HCC) remains one of the deadliest malignancies globally, posing substantial health threats and economic burdens. Despite advances in therapeutic modalities-including surgical resection, liver transplantation, and targeted therapies-HCC prognosis remains unsatisfactory. This highlights an urgent need for novel biomarkers to improve prognostic stratification. Senescence-related genes (SRGs) have emerged as promising candidates for HCC prognostic exploration, making their association with clinical outcomes the focus of this study.​.&lt;h4>Methods&lt;/h4>Comprehensive machine learning was applied to screen SRGs associated with HCC survival, identifying key prognostic genes. A clinical nomogram based on SRG scores was constructed and validated. NAP1L4 expr</pubmed_abstract><journal>Discover oncology</journal><pubmed_title>NAP1L4 in hepatocellular carcinoma progression and treatment from gene expression to clinical impact.</pubmed_title><pmcid>PMC12708435</pmcid><funding_grant_id>No.202304295107020040</funding_grant_id><funding_grant_id>No. 2022AH040160</funding_grant_id><funding_grant_id>No. 82370608</funding_grant_id><funding_grant_id>No.2208085MH204</funding_grant_id><pubmed_authors>Kong L</pubmed_authors><pubmed_authors>Shen J</pubmed_authors><pubmed_authors>Han K</pubmed_authors><pubmed_authors>Liu M</pubmed_authors><pubmed_authors>Xie Z</pubmed_authors><pubmed_authors>Chen G</pubmed_authors><pubmed_authors>Yao R</pubmed_authors><pubmed_authors>Xu H</pubmed_authors><pubmed_authors>Yin H</pubmed_authors><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Wang Q</pubmed_authors><pubmed_authors>Gao Y</pubmed_authors><pubmed_authors>Lin J</pubmed_authors></additional><is_claimable>false</is_claimable><name>NAP1L4 in hepatocellular carcinoma progression and treatment from gene expression to clinical impact.</name><description>&lt;h4>Background&lt;/h4>Hepatocellular carcinoma (HCC) remains one of the deadliest malignancies globally, posing substantial health threats and economic burdens. Despite advances in therapeutic modalities-including surgical resection, liver transplantation, and targeted therapies-HCC prognosis remains unsatisfactory. This highlights an urgent need for novel biomarkers to improve prognostic stratification. Senescence-related genes (SRGs) have emerged as promising candidates for HCC prognostic exploration, making their association with clinical outcomes the focus of this study.​.&lt;h4>Methods&lt;/h4>Comprehensive machine learning was applied to screen SRGs associated with HCC survival, identifying key prognostic genes. A clinical nomogram based on SRG scores was constructed and validated. NAP1L4 expr</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-09T03:15:15.435Z</modification><creation>2026-06-09T03:07:29.745Z</creation></dates><accession>S-EPMC12708435</accession><cross_references><pubmed>41258556</pubmed><doi>10.1007/s12672-025-04016-7</doi></cross_references></HashMap>